Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained from the subject.~* Aged 18 years or above at screening.~* In good general health~* Subject available for the study duration~* For female subjects (of child bearing potential) a negative pregnancy tests at Screening and Day 0.~Exclusion Criteria:~* A history of vaccination against or infection with JE.~* Known or suspected immunodeficiency, use of immunosuppressive or antineoplastic drugs.~* History of thymoma, thymic surgery (removal) or myasthenia gravis.~* Clinically significant abnormalities on laboratory assessment~* Anaphylaxis or other serious adverse reactions characterised by urticaria or angioedema to foods, Hymenoptera (bee family) stings, or drugs including vaccines).~* Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit or up to Day 30.~* Administration of another vaccine or antiviral within 30 days preceding the Screening visit or up to Day 30.~* Physical examination indicating any clinically significant medical condition.~* Oral temperature \>38°C (100.4°F) or acute illness within 3 days prior to inoculation.~* Intention to travel out of the area for an extended period that may affect the subjects ability to attend clinic visits prior to the study visit up to Day 30.~* Seropositive to hepatitis C virus (HCV) or HIV or positive for Hepatitis B Surface Antigen.~* Lactation or intended pregnancy in female subjects.~* Excessive alcohol consumption, drug abuse, significant psychiatric illness.~* A known or suspected physiological or structural condition that compromises the integrity of the blood-brain barrier (e.g. cerebrovascular disease, multiple sclerosis, trauma, infection, inflammation of the brain or meninges).~* Participation in another clinical study within 30 days of the screening visit for this study.~* Employee of the study site, Sponsor or Clinical Research Organization (CRO) involved with the management of the study.~* Any other reasons, which in the investigator's opinion, makes the subject unsuitable to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): All subjects received a single injection of placebo on Day 0.
- ChimeriVax™ JE 4 log10 PFU Vaccine (Type: EXPERIMENTAL): All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).